دورية أكاديمية
أعرض في EDS

Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma.
المؤلفون: Vorbach SM; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Mangesius J; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Dejaco D; Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria., Seppi T; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Santer M; Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria., Zur Nedden S; CCB-Biocenter, Institute of Neurobiochemistry, Medial University of Innsbruck, 6020 Innsbruck, Austria., Sarcletti MP; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Pointner MJ; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Hart TJ; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Riechelmann H; Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria., Ganswindt U; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Nevinny-Stickel M; Department of Radiation-Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
المصدر: Cancers [Cancers (Basel)] 2023 Nov 01; Vol. 15 (21). Date of Electronic Publication: 2023 Nov 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Current literature regarding survival and treatment outcome of SBRT in patients with pulmonary oligometastatic head and neck squamous cell carcinoma (HNSCC) is limited. Additionally, most of the published studies include metastatic lesions deriving also from primaries with histologies other than SCC when investigating the outcome of SBRT. The aim of the present retrospective study is to explore local control (LC) of treated metastases, progression-free survival (PFS), and overall survival (OS) of exclusively pulmonary oligometastatic HNSCC-patients treated with SBRT. Between 2006 and 2021, a total of 46 patients were treated with SBRT for a maximum of four pulmonary oligometastases (PM) concurrently (mean PM per patient = 2.0; range 1 to 6 PM, total of 92). Of these, 17 patients (37.0%) developed new pulmonary metastases after their first SBRT. Repeated courses of SBRT were required once in 15 patients (88.2%) and twice in 2 patients (11.8%). Median follow-up was 17 months (range, 0-109 months). One year after completion of SBRT, LC rate, PFS, and OS were 98.7%, 37.9%, and 79.5%, respectively. After two years, LC rate, PFS, and OS were 98.7%, 28.7%, and 54.9%; as well as 98.7%, 16.7%, and 31.0% after five years. Radiochemotherapy (HR 2.72, p < 0.001) or radiotherapy as primary treatment (HR 8.60; p = 0.003), as well as reduced patient performance status (HR 48.30, p = 0.002), were associated with lower PFS. Inferior OS correlated with poor performance status (HR 198.51, p < 0.001) and surgery followed by radiochemotherapy (HR 4.18, p = 0.032) as primary treatment, as well as radiotherapy alone (HR 7.11, p = 0.020). Treatment of more than one PM is an independent predictor of impaired OS (HR 3.30, p = 0.016). SBRT of HNSCC-derived PMs results in excellent LC rates and encouraging OS rates of 54.9% at two years along with good tolerability (no more than grade 2 toxicities). Favourable outcome and low toxicity also apply to repeated courses of SBRT of newly emerging PMs.
References: Laryngoscope. 2021 May;131(5):E1476-E1480. (PMID: 33044014)
J Clin Oncol. 1995 Jan;13(1):8-10. (PMID: 7799047)
Oral Oncol. 2019 Jan;88:131-136. (PMID: 30616783)
BMJ Open. 2019 Feb 19;9(2):e025359. (PMID: 30782931)
Radiat Oncol. 2021 Mar 31;16(1):62. (PMID: 33789725)
Cancers (Basel). 2016 Aug 05;8(8):. (PMID: 27527216)
Radiat Oncol. 2015 Feb 18;10:43. (PMID: 25889747)
J Radiosurg SBRT. 2022;8(1):11-19. (PMID: 35387401)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Ann Oncol. 2010 Oct;21 Suppl 7:vii252-61. (PMID: 20943624)
Head Neck. 2019 Jul;41(7):2309-2314. (PMID: 30788878)
Cancers (Basel). 2021 Dec 01;13(23):. (PMID: 34885170)
Radiother Oncol. 2020 Jan;142:230-235. (PMID: 31481272)
Head Neck. 2017 Sep;39(9):1733-1743. (PMID: 28650113)
Br J Radiol. 2017 Mar;90(1071):20160732. (PMID: 27885858)
J Thorac Oncol. 2020 Jan;15(1):101-109. (PMID: 31479748)
J Clin Oncol. 2021 Jan 1;39(1):30-37. (PMID: 32822275)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Case Rep Oncol. 2019 Sep 25;12(3):728-736. (PMID: 31616281)
Radiat Oncol. 2017 Feb 1;12(1):35. (PMID: 28143558)
Am J Surg. 1987 Oct;154(4):439-42. (PMID: 3661849)
Nat Rev Clin Oncol. 2010 Jan;7(1):44-54. (PMID: 19997074)
ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):202-7. (PMID: 11408812)
Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
BMC Cancer. 2023 Apr 12;23(1):337. (PMID: 37046249)
Oral Oncol. 2019 Jun;93:1-7. (PMID: 31109688)
Cancer Med. 2022 Mar;11(6):1553-1560. (PMID: 35029329)
Radiother Oncol. 2018 May;127(2):246-252. (PMID: 29510865)
Acta Oncol. 2019 Mar;58(3):390-392. (PMID: 30764696)
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):611-616. (PMID: 35643253)
Cancers (Basel). 2022 Aug 11;14(16):. (PMID: 36010888)
Ann Thorac Surg. 2009 Sep;88(3):856-60. (PMID: 19699911)
Lancet. 2019 May 18;393(10185):2051-2058. (PMID: 30982687)
Br J Radiol. 2011 Nov;84(1007):967-96. (PMID: 22011829)
J Clin Oncol. 2018 Apr 10;36(11):1143-1169. (PMID: 29172863)
Head Neck. 2023 Oct;45(10):2627-2637. (PMID: 37602655)
Oral Oncol. 2012 Sep;48(9):787-93. (PMID: 22516376)
J Clin Oncol. 2015 Oct 10;33(29):3305-13. (PMID: 26351341)
Semin Radiat Oncol. 2003 Jul;13(3):176-81. (PMID: 12903007)
Head Neck. 2020 Aug;42(8):1939-1953. (PMID: 32129548)
Lung Cancer. 2013 Feb;79(2):161-6. (PMID: 23182662)
J Cancer Res Clin Oncol. 2021 May;147(5):1307-1313. (PMID: 33471186)
J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100. (PMID: 17603311)
Radiother Oncol. 2020 Jul;148:157-166. (PMID: 32388150)
Cancers (Basel). 2023 May 18;15(10):. (PMID: 37345157)
Radiother Oncol. 2009 Jul;92(1):4-14. (PMID: 19446902)
J Clin Oncol. 2006 Jun 10;24(17):2606-11. (PMID: 16763272)
فهرسة مساهمة: Keywords: head and neck squamous cell carcinoma; pulmonary oligometastases; repeated courses of SBRT; stereotactic body radiotherapy
تواريخ الأحداث: Date Created: 20231114 Latest Revision: 20231117
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10647772
DOI: 10.3390/cancers15215253
PMID: 37958426
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15215253